|
|
Oxford BioMedica plc - Comparative Business Analysis Snapshot
Business Description
Oxford BioMedica plc. The Group's principal activity is researching and developing genebased medicines and therapeutic vaccines based on a broad technology platform. The Group's development pipeline comprises four products in clinical development and a late-stage preclinical candidate. The lead product is TroVax,a therapeutic vaccine that has potential application in a range of tumour types. The product is designed to stimulate a specific anti-cancer immune response against a protein called 5T4. The Group's other products are Hi-8 MEL, MetXia, ProSavin and RetinoStat. The Group operates in the United Kingdom and the United States of America.
Competitor Analysis
This analysis compares Oxford BioMedica plc with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
